Merck to acquire coronavirus vaccine candidate developer Themis Bioscience
Merck acquisition of Themis Bioscience : Merck has signed a deal to acquire Themis Bioscience, an Austrian vaccine developer for an undisclosed price with an objective to gain access to the latter’s coronavirus vaccine candidate. Themis Bioscience by leveraging its measles virus vector platform has developed a pipeline of vaccine candidates and immune-modulatory therapies. Recently, […]